Greenwich LifeSciences (GLSI) Q4 2024 earnings summary

Executive summary

• Clinical-stage biopharmaceutical company focused on Phase III trial (Flamingo-01) for GLSI-100, an immunotherapy targeting prevention of breast cancer recurrence in HER2/neu positive patients.

• No revenue generated to date; operations funded by equity offerings and private placements.

• Net losses increased to $15.8 million in 2024 from $8.9 million in 2023, driven by higher R&D and G&A expenses.

• Cash balance at year-end 2024 was $4.1 million, with additional capital raised post-year-end via ATM offerings.

Financial highlights

• Research and development expenses rose 68% year-over-year to $13.0 million in 2024, mainly due to Phase III trial costs and one-time option vesting.

• General and administrative expenses increased 88% to $3.1 million, also impacted by option vesting.

• Net loss for 2024 was $15.8 million, or $1.21 per share, compared to $8.9 million, or $0.69 per share, in 2023.

• Cash used in operations was $7.3 million in 2024; financing activities provided $4.4 million, primarily from equity sales.

• Accumulated deficit reached $66.2 million as of December 31, 2024.

Outlook and guidance

• Existing cash expected to fund operations for at least 12 months from the report date, but not sufficient to complete development or obtain regulatory approval for GLSI-100.

• Additional capital will be required for ongoing clinical trials, regulatory submissions, and potential commercialization.

• Strategic alternatives, including partnerships or sale of the company, may be considered to maximize shareholder value.